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Background: Although recent studies have found that total plasma homocysteine (tHCY) 
and chronic obstructive pulmonary disease (COPD) are both risk factors for cardiac disease, 
there have been few studies of plasma homocysteine levels in COPD patients. We tested the 
hypothesis that total plasma homocysteine (tHCY) would be elevated in patients diagnosed 
with COPD compared with controls.
Methods: We studied 29 COPD outpatients and 25 asymptomatic subjects (controls) over 
age 55 years with measurement of forced expiratory volume in one second (FEV1), forced 
vital capacity (FVC), St. Georges Respiratory Questionnaire (SGRQ) score, tHCY and serum 
C-reactive protein (sCRP).
Results: There was no difference between controls vs. COPD patients in mean age or gender 
but mean (SD) FEV1 was 2.25 (0.77) vs 1.43 (0.60) L; FEV1% predicted 76.1 (17.2) vs 49.1 
(16.3) p  0.001 in both cases. Median (IQR) tHCY was 8.22 (6.63, 9.55) in controls vs 10.96 
(7.56, 13.60) micromol/l for COPD, p = 0.006 and sCRP 0.89 (0.47, 2.55) vs 2.05 (0.86, 6.19) 
mg/l, p = 0.023. tHCY(log) was also higher in (r, p) smokers (0.448, 0.001), patients with low 
FEV1% (−0.397, 0.003), males (0.475, 0.001), but high SGRQ Total score (0.289, 0.034), 
and high sCRP (0.316, 0.038). tHCY(log) was independently related to (regression coefﬁ  cient, 
p) sCRP(log) (0.087, 0.024), male gender (0.345, 0.001) and presence of COPD (0.194, 
0.031). Median (IQR) tHCY GOLD Stage I and II 8.05 (7.28, 11.04), GOLD Stage III and IV: 
11.83(9.30, 18.30); p = 0.023.
Conclusions: Plasma homocysteine is signiﬁ  cantly elevated in COPD patients relative to age 
and sex-matched controls and is related to serum CRP and COPD severity.
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Introduction
There has been an increase in the prevalence of and mortality from chronic obstructive 
pulmonary disease (COPD) worldwide. The World Health Organization has predicted 
that by 2020, COPD will rise from its current ranking as the 12th most prevalent 
disease worldwide to the 5th and from the 6th most common cause of death to the 
3rd (Barnes 2000). Amongst the reasons for the dramatic increase in COPD preva-
lence include reduced mortality from other causes such as cardiovascular diseases in 
industrialized countries and infectious diseases in developing countries, along with 
a marked increase in cigarette smoking and environmental pollution in developing 
countries (Barnes 2000).
Chronic obstructive pulmonary disease is characterized by airﬂ  ow limitation that is not 
fully reversible, progressive, associated with an abnormal inﬂ  ammatory response of the 
lungs to noxious particles or gases (Buist 2006) and the presence of low grade systemic 
inﬂ  ammation (Wedzicha 2000; Sin 2003). Amongst the systemic inﬂ  ammatory markers 
serum C-reactive protein (sCRP) has emerged as a major systemic indicator of vascular 
risk (Danesh 1998; Sin 2003). However recent studies have demonstrated that plasma International Journal of COPD 2007:2(3) 314
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homocysteine may be considered to be a strong marker of car-
diovascular risk (Homocysteine Studies 2002; Bodi 2005).
Most studies which have looked at systemic mechanisms and 
vascular risk in COPD have been undertaken in developed world 
subjects (Barnes 2000; Wedzicha 2000; Sin 2003) but in the West 
Indies there are lifestyle differences compared with the developed 
world and risk factors for morbidity and mortality may differ. 
Epidemiological studies of diseases in Trinidad and Tobago have 
concentrated on cardiovascular and metabolic diseases without 
much reference to respiratory diseases apart from asthma (Miller 
1989; Scott 1998; PintoPereira 2002; Cockburn 2005), however 
a recent study of COPD in Trinidad has reported that patients 
with a history of vascular disease (VD) are more likely to have a 
low forced expiratory volume in one second (FEV1) (Harrinarine 
2005). We postulated that blood markers of cardiac risk (tHCY 
and sCRP) would be elevated in COPD patients and that there 
would be an inverse relation between these markers of cardiac 
risk and spirometric indices of airway obstruction.
Methods
Selection of COPD patient and controls
Patients were recruited in 2005 from the Chest Clinic at Eric 
Williams Medical Sciences Complex (EWMSC), Faculty of 
Medical Sciences, St. Augustine, Trinidad and Tobago and all 
were outpatients who were know to have COPD. Asymptom-
atic subjects (controls) for this study were recruited during the 
study period in response to advertisement. The recruitment 
record included demographic variables, smoking, medical 
history and diet (Refsum 2004).
Ethical permission was obtained from the Institutional 
Review Board of the University of the West Indies prior to 
recruitment. Subjects were informed of the study and gave 
written consent prior to participating in the study.
Inclusion criteria for COPD patients
A prior diagnosis of COPD stated in the patients’ medical 
notes and postbronchodilator FEV1/forced vital capacity 
(FVC) ratio of less than 70% (Buist 2006). All COPD patients 
were over the age of ﬁ  fty-ﬁ  ve years.
Inclusion criteria for controls
Asymptomatic controls were deﬁ  ned as persons over the age 
of ﬁ  fty-ﬁ  ve years without any known medical illness and 
who were symptom free.
Exclusion criteria for COPD patients
Patients were excluded with any of the following (AARC 
1996; Wedzicha 2000; Refsum 2004): hemoptysis of 
unknown origin; pneumothorax; unstable cardiovascular 
status, recent myocardial infarction or pulmonary embolus 
thoracic; abdominal or cerebral aneurysms; recent eye sur-
gery eg, cataract; presence of an acute disease process that 
might interfere with test performance; recent surgery of 
thorax or abdomen; acute infection, inﬂ  ammatory diseases 
such as rheumatoid arthritis, or history of kidney disease.
Exclusion criteria for controls
The exclusion criteria for the controls were the presence of any 
known disease or presence of any acute or chronic symptoms.
Measurement of spirometric variables
A handheld turbine spirometer (MicroSpirometer Cat No: 
MS01 Micromedical Limited P.O Box 6 Rochester, Kent, 
ME1 2AZ, UK) was used to measure postbronchodilator FEV1 
and FVC. The spirometer met the requirements of the Ameri-
can Thoracic Society (ATS) (ATS 1994) and was calibrated 
appropriately (AARC 1996) and did not require recalibration 
(Seemungal 2000). Post-bronchodilator spirometric indices 
were measured 20 minutes after the subject inhaled two puffs 
of salbutamol -100 μg (AARC 1996). COPD severity (Crapo 
1981) was classiﬁ  ed according to the Global Initiative for 
Obstructive Lung Disease (GOLD) (Buist 2006).
Sample collection and analysis
Nonfasting venous blood samples were obtained from subjects 
for serum CRP analysis and plasma samples with ethylene 
diamine tetra acetic acid (EDTA) as anticoagulant used for 
tHCY analysis. The latter were immediately placed on ice in 
an icebox after collection and centrifuged within two hours, 
samples were stored at −20 °C until analysis within one month. 
The Abbott AxSym Homocysteine assay was utilized to quanti-
tatively measure tHCY levels. It was based on the Fluorescence 
Polarization Immunoassay (FPIA) technology. This assay had 
a within day and day to day imprecision of (CV  5%) and a 
recovery of 99.6%. Intraassay imprecision 1.1–1.8%, interassay 
2.4%–6.7%. with an analytical sensitivity of 0.7 μmol/L. Serum 
CRP concentrations were measured using the Tina-Quant 
sCRP (Latex) high sensitive immunoturbidimetric assay on the 
Roche/Hitachi 912 Automatic Analyzer (Roche Diagnostics, 
GmbH, D-68298 Mannheim). The measuring range was 0.1–20 
mg/L with a detection limit of 0.03 mg/L.
Health related quality of life and dietary 
vitamin intake
Health related quality of life
The health related quality of life (HRQOL) was determined 
using the St. George’s respiratory questionnaire (SGRQ) International Journal of COPD 2007:2(3) 315
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(Jones 1991). The SGRQ is a disease speciﬁ  c instrument that 
contains 50 items in 3 subscales (Symptoms, Activity, and 
Impact) (Jones 1991). The 3 components are transformed into 
a score from 0 to 100 (Jones 1991). The total score was cal-
culated from responses to all 50 items (Jones 1991). Higher 
scores indicate poorer health status. The SGRQ was modiﬁ  ed 
for use in Trinidad and was reviewed by four authors (TARS, 
GD, LPP, JD) using the MAPI Research Institute Method 
(Davison 2004). The only change made to the questionnaire 
was replacing the culturally (for the West Indies) irrelevant 
item “shovelling snow” by “dig in garden” in Section 6. 
This change did not affect the sense of the questionnaire and 
thus the weighting of the various parts of the questionnaire 
remained unchanged (Broekhuizen 2005).
Dietary vitamin intake
The food frequency questionnaire (FFQ) (Nutrition 
Assessment Shared Resource, 1100 Fairview Ave. N. 
M1-B208 Seattle, WA 98109-1024) was used to assess 
Vitamin B6, B12, and folate status in individuals according 
to the United States dietary allowance (USDA) National 
Nutrient Database for Standard Reference (National Agri-
cultural Library 2004) since deﬁ  ciencies in folate, Vitamins 
B6 and B12 can lead to hyperhomocysteinaemia (Refsum 
2004). The FFQ was used to estimate habitual food intake 
of individuals and it consisted of a list of food items and a 
set of frequency-of-use response categories eg, per day, per 
week, per month or per year. Open-ended questions were 
avoided. Data gathered with the FFQ was ranked in classes 
of small, medium and large intakes (National Agricultural 
Library 2004) and the total intake scored (Fabiosa 1997). 
To evaluate the nutritional outcomes, the nutrient intake 
levels were compared with their respective United States 
recommended dietary allowances (RDAs) to determine the 
degree of shortfall (or excess) from the RDAs. In order to 
be comparable to the RDA standard, the nutrient intake was 
expressed on a per day basis (Fabiosa 1997).
Statistical analysis
Since there was no previously published West Indian data 
on homocysteine levels in the age groups studied the sample 
size was estimated using data from a previous study of 
inﬂ  ammatory markers in COPD (Wedzicha 2000). In the 
latter study, the mean plasma ﬁ  brinogen in COPD patients 
was 33% higher when compared to normal age-matched 
subjects. In our study, we assumed a more conservative 
difference of 16.5% for the means of tHCY between normal 
and COPD subjects while allowing for the similar differences 
in variability observed in plasma ﬁ  brinogen. In order to 
detect a rise of 16.5% in mean tHCY between normal and 
COPD subjects, with a statistical power of 90% at the 5% 
signiﬁ  cance level, we calculated a sample size of 23 subjects 
in each group.
For analysis, patients were classiﬁ  ed as either smokers if 
they ever smoked or as nonsmokers. Categorical data were 
expressed in number (percentage). Parametric continuous 
variables were expressed as mean (SD) (standard deviation) 
while non-parametric continuous variables were expressed 
as median (interquartile range). sCRP were both normalized 
by logarithmic transformation and so Pearson’s correlation 
was used to determine binary relationships with these two 
variables. Differences between continuous variables were 
determined by t-test or Mann Whitney U-test as appropriate. 
Categorical variables were compared by the chi-square test. 
Backward linear regression, with tHCY(log) as outcome 
variable, was used to determine independent effects of vari-
ables that showed signiﬁ  cant univariate relationship with 
tHCY(log).
Results
Demographics and spirometry
Table 1 shows that a total of 54 subjects (ethnicity: African 
18, East Indian 25, Chinese 2, Mixed ancestry 9) were 
recruited of which 25 were controls and 29 were COPD 
patients. Among all subjects, older patients were more likely 
to have a lower FEV1 (rho = −0.557, p = 0.002) and FVC 
(−0.487, 0.007). Also there was no signiﬁ  cant difference 
between Africans and East Indians in age, gender, body 
mass index, FEV1% predicted or FEV1/FVC% (p  0.05 
in all cases).
COPD patients had a lower body mass index (BMI) 
than asymptomatic controls but age, height, ethnicity and 
gender distribution were similar (Table 1). In the asymp-
tomatic controls, 22 never smoked, 2 quit greater than one 
year prior to the study and one quit within the past twelve 
months. In the COPD group, 5 never smoked, 13 quit greater 
than 1 year ago, 3 quit within the past year and 8 currently 
smoked. Co-morbidities amongst the 29 COPD patients 
were as follows: 12 in all with either cardiac disease (N = 9) 
and/or diabetes mellitus (N = 6). The distribution of COPD 
severity amongst COPD patients was: GOLD stages 1 and 
2 (N = 15), GOLD stages 3 and 4 (N = 14).
Quality of life
As expected, Table 1 shows that the SGRQ total and com-
ponent scores were uniformly higher in COPD patients com-International Journal of COPD 2007:2(3) 316
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pared with controls. The SGRQ total and component scores 
were strongly correlated with each other with correlations 
ranging from 0.622 to 0.933 (p  0.001 in all cases). Table 
2 shows that the SGRQ total and component scores were 
higher in COPD patients and those with low FEV1, FEV1% 
and FEV1/FVC (p  0.001 in all cases). The SGRQ scores 
were all higher in the smokers.
Total plasma homocysteine and serum 
C-reactive protein
Table 1 shows that median tHCY and median sCRP were 
higher in the COPD patients. Since this is the ﬁ  rst study of 
homocysteine in this population we also state the means for 
comparison: mean (SD) tHCY in asymptomatic controls 
was 8.18 (1.82) μmol/L and in COPD patients 11.96 (5.87) 
μmol/L; mean (SD) sCRP was 1.83 mg/L in the asymptomatic 
controls and 4.35 mg/L in the COPD group. COPD patients 
with cardiac disease or diabetes mellitus were unlikely to 
have a higher plasma homocysteine or serum CRP level than 
other COPD patients (p  0.120 in all cases). There was no 
signiﬁ  cant relationship between ethnicity and tHCy or sCRP. 
Further, tHCY was not related to B12, folic acid or B6 intake 
as estimated by the food frequency questionnaire (p  0.200 
in all cases). 25% of patients consumed alcohol, but this was 
unrelated to tHCY levels, rho = 0.070, p = 0.668.
Table 3 shows that higher levels of tHCY and sCRP were 
found in COPD patients, smokers and Table 2 shows that 
higher levels of tHCY and sCRP were also related to higher 
SGRQ symptoms, impacts, and total scores. In addition, 
tHCY was likely to be higher in males and to low FEV1% 
predicted or low FEV1/FVC. tHCY(log) and sCRP(log) 
were signiﬁ  cantly correlated over all subjects as illustrated 
in Figure 1.
Figure 2 shows that COPD patients with high stage dis-
ease (GOLD stages 3 and 4) were more likely to have a high 
tHCY (rho = 0.429, p  0.020) than those with low stage 
disease (GOLD stages 1 and 2). There was a nonsigniﬁ  cant 
Table 1 Demographical data, lung function, SGRQ scores, tHCY and sCRP among controls and COPD patients. Data is shown either 
as mean (SD) or median (25th centile, 75th centile)
Characteristics Controls  (N = 25) COPD  (N = 29) p-value
Age/yrs mean (SD)  64.8 (6.8)  69.1 (9.8)  0.137
Height/cms  164.3 (9.3)  164.8 (9.2)  0.849
Gender: Male N (%)  16 (64)  23 (79)  0.218
Ethnicity N (%)*      0.061
  East Indians (Indo-Trinidadian)  9 (36)  16 (55) 
  African (Afro-Trinidadian)  8 (32)  10 (35) 
  Other   8 (32)  3 (10) 
BMI kg/m2 (median (IQR)  27.4 (25.9, 29.9)  24.0 (20.5, 27.0)  0.001
Lung Function (mean (SD))     
FEV1 /L  2.25 (0.77)  1.43 (0.60)  0.001
FVC /L  2.91 (1.02)  2.72 (0.82)  0.18
FEV1/FVC %  78.1 (8.3)  53.1 (14.0)  0.001
FEV1 % predicted  76.1 (17.2)  49.1 (16.3)  0.001
SGRQ Scores (median (IQR))     
  Impact  0.0 (0.0, 0.0)  35.7 (10.0, 50.8)  0.001
  Activity  6.2 (0.0,12.2)  47.7 (26.0, 66.3)  0.001
  Symptoms  0.0 (0.0,8.1)  49.3 (19.1, 64.0)  0.001
  Total  2.8 (0.0, 9.3)  44.2 (18.4, 55.0)  0.001
tHCY/micromol/L  8.22 (6.63, 9.55)  10.96 (7.56,13.60)  0.006
sCRP/mg/L  0.890 (0.47, 2.55)  2.050 (0.86, 6.19)  0.023
Abbreviations: SD, standard deviation; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; SGRQ, St. George’s Respiratory Questionnaire; tHCY, total 
plasma homocysteine; sCRP, serum C-reactive protein; BMI, Body Mass Index.
Note: *Ethnicity was determined from the patient’s own perception.
Table 2 Correlations (Spearmans) between variables in Table 1 
and SGRQ symptoms, impacts, activities and total scores, 
(N = 54 subjects). (NS = Not statistically signiﬁ  cant)
Variable Symptoms  Impacts  Activities  Total  score
FEV1***  −0.498  −0.461  −0.516  −0.595
FEV1%***  −0.584  −0.577  −0.620  −0.644
FEV1/FVC***  −0.576  −0.641  −0.437  −0.558
BMI*  −0.278  −0.338 NS  NS
Smoker* 0.555  0.649 0.448  0.582
tHCY* 0.295  0.330  NS  0.289
sCRP* 0.339 0.286  NS  0.316
Note: ***p  0.001 for all correlations in this row; *p  0.05 for all correlations 
in this row. Except where NS is stated.International Journal of COPD 2007:2(3) 317
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trend toward a higher median sCRP in patients with high vs. 
low stage COPD (3.48 vs. 1.64 mg/L, p = 0.565). However 
tHCY and sCRP were signiﬁ  cantly related in the COPD 
patients (N = 29), rho = 0.415, p = 0.025.
Multivariate analysis of factors affecting 
plasma homocysteine levels
Backward multiple regression for all subjects (N = 54) with 
plasma homocysteine (log) as outcome variable revealed 
independent relationships with serum CRP (log), presence of 
COPD and male gender but not SGRQ Total score (dichoto-
mized about the median) or smoking history (Table 4). If the 
regression was repeated with FEV1% instead of presence of 
COPD as the lung function variable results were similar, with 
an inverse relationship between FEV1% and tHCY(log).
When the regression analysis was repeated amongst 
COPD patients only (N = 29), tHCY(log) was independently 
related to high sCRP (log) (B = 0.123, p = 0.046) and high 
stage COPD [GOLD 3 and 4] (B = 0.326, p = 0.023) and, 
again, effects of quality of life and smoking could not be 
independently distinguished.
Discussion
This is the ﬁ  rst study to our knowledge that shows the rela-
tionship between plasma tHCY and spirometric measure-
ments in a West Indian population, the study extends and 
supports the ﬁ  ndings of two previous studies (Anderson 
2001; Kai 2005). We found a negative correlation between 
FEV1 and tHCY in the subjects studied and, consistent with 
other centres, a high sCRP in COPD patients (Broekhuisen 
2005; Dahl 2007). tHCY and sCRP were related to COPD 
severity using the GOLD guidelines classiﬁ  cation and this 
relationship was supported by relationships with poor quality 
of life scores in the bivariate analyses. Total plasma homo-
cysteine was greater in men, subjects with low FEV1/FVC 
ratio and low FEV1 % predicted. Our study revealed a posi-
tive correlation between tHCY and sCRP in both patients 
and controls.
This is the ﬁ  rst study to measure health-related quality of 
life in a West Indian COPD population using the SGRQ and 
the ﬁ  rst to show a relationship with plasma homocysteine. 
Several instruments have been advocated for measurement 
of quality of life; however as with most questionnaires of 
this type, they may be rather insensitive to changes in health 
(Jones 1991). The SGRQ has the advantage of allowing direct 
comparison between different patient populations and treat-
ment groups and has been shown to be responsive when used 
for these comparisons (Jones 1991; Seemungal 1998). The 
Total SGRQ score in our group of COPD patients was 44.2 
as compared with 56.7 in the East London cohort of moder-
ate to severe COPD patients (Seemungal 1998), like the East 
London Study, all of our COPD patients were outpatients. 
In this study we presented the data for SGRQ in the controls 
as this is the ﬁ  rst study of its kind in the West Indies. As in 
other studies we have found a relationship between impaired 
quality of life, severity of airﬂ  ow obstruction and eleva-
tion of the serum inﬂ  ammatory marker C-reactive protein 
(Broekhuisen 2005).
tHCY was unrelated to dietary vitamin (B12, folate 
and B6) intake however, median tHCY in COPD patients 
was higher when compared with controls, and in smokers 
compared with nonsmokers. In the multivariate analysis 
the effects of COPD outweighed those of smoking indicat-
ing that by the time that COPD develops the events that 
lead to rising tHCy may be independent of the smoking 
stimulus. Our results support those of a recent study in a 
Japanese population (Kai 2005) who like us found a mean 
plasma homocysteine of approximately 12 μmol/L in the 
COPD patients and showed that a high tHCY predicted 
more rapid FEV1 decline. However, we have also found 
that tHCY is related to COPD severity which they did not 
(Kai 2005). Unlike the Japanese cohort the FEV1 of our 
patients was negatively correlated with tHCY levels and 
this is consistent with the relationship we found between 
high tHCY and poor quality of life scores. Kai and col-
leagues (2005) found that there was a tendency toward a 
relationship between low arterial oxygen tension and low 
tHCY in their COPD patients and speculated that this may 
cause inhibition of enzymes involved in tHCY metabolism 
in the later stages of COPD, however this relationship was 
Table 3 Correlations (Pearsons) between tHCY(log), sCRP(log) 
and the baseline variables. (Statistically signiﬁ  cant relationships 
are in bold type, p  0.05, N = 54 subjects.)
 tHCY(log)    sCRP(log)
 rho  p  rho  p
COPD 0.418  0.002  0.327  0.016
Male Gender  0.475  0.001 0.059  0.672
Age 0.223  0.105  0.173  0.212
BMI  −0.120 0.387  −0.091 0.514
Ethnicity  −0.191 0.169  −0.193 0.161
Smoker 0.448  0.001  0.410  0.002
FEV1   −0.168 0.226  −0.263 0.055
FVC 0.000  - −0.211 0.126
FEV1 /FVC  −0.298 0.028  −0.225 0.102
FEV1% Predicted  −0.397 0.003  −0.272 0.047
tHCY -  -  0.377  0.005International Journal of COPD 2007:2(3) 318
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not tested in a multivariate analysis. We note however that 
the mean FEV1 of our patients was greater than that in the 
Japanese study and so on average our patients were less 
severe. Several enzymes are involved either directly or 
indirectly in homocysteine metabolism and mutations in 
any of the following cystathionine beta-synthase (Mudd 
2001), methylenetetrahydrofolate reductase (MTHFR) or 
methionine synthase reductase (Goyette 1995; Kluijitmans 
2003) may contribute to hyperhomocysteinaemia in differ-
ent populations.
The high levels of tHCY in COPD compared with the 
controls may well be a marker of unhealthy lifestyles (Rimm 
1998; Cleophas 2000). However the ﬁ  nding that tHCY was 
higher in patients with GOLD stages III/IV disease compared 
with Stages I/II suggests a role in COPD pathogenesis. This 
is supported by the ﬁ  nding of an inverse relationship between 
tHCY and FEV1% as well as with poor quality of life scores. 
The raised tHCY in COPD has been related to oxidative stress 
as demonstrated by Andersson et al who showed that tHCY 
was elevated, but reduced glutathione depressed, in COPD 
relative to controls (Anderson 2001). Thus, the role of tHCY 
in COPD may be mediated through its inverse relationship 
with reduced glutathione. Recent workers have found a rela-
tionship between markers of oxidative stress such as reduced 
glutathione and COPD severity and this is consistent with our 
hypothesis of a role for tHCY in the pathogenesis of COPD 
(Kluchova 2006; Vibhuti 2007).
We found that tHCY levels were positively and indepen-
dently related to sCRP, a marker of systemic inﬂ  ammation, 
mortality and hospitalization in COPD (Dahl 2007), cardiac 
disease (Zakai 2007) and cardiac disease in COPD (Sin 
2003). In our study, median sCRP in normal subjects was 
similar to that of previously published American and Dutch 
controls (Sin 2003; Broekhuisen 2005). The difference 
-2.00 -1.00 0.00 1.00 2.00 3.00 4.00
sCRP(log)
1.50
2.00
2.50
3.00
3.50
Patient 
Classification
Control
COPD
tHCY(log)
Figure 1 Relationship between total plasma homocysteine (tHCY) and serum C-reactive protein (sCRP) in 29 COPD patients and 25 asymptomatic controls, rho = 0.377, 
p = 0.005. Grey circles are asymptomatic controls and black circles are COPD.International Journal of COPD 2007:2(3) 319
Plasma homocysteine is elevated in COPD and related to COPD severity and high CRP
in mean sCRP between controls and COPD patients was 
2.52 mg/L in our study which is of the same order of 
magnitude as the 1.86 mg/L due to COPD as estimated 
in a meta-analysis by Gan and colleagues (2004). In our 
study we have found that circulating levels of sCRP were 
higher in participants with airﬂ  ow obstruction than in those 
without and that sCRP was related to severity of obstruc-
tion as Sin and colleagues (2003) found. However, though 
median sCRP was higher in our more severe COPD patients 
the sample size was not sufﬁ  cient to detect a statistically 
signiﬁ  cant difference. Like tHCY, sCRP is also associated 
with cardiac disease (Zakai 2007). Pulmonary inﬂ  ammation 
is a likely cause of systemic inﬂ  ammation seen in COPD, 
as supported by a recent study showing that use of inhaled 
corticosteroids in COPD patients is associated with reduced 
sCRP and other markers of systemic inﬂ  ammation (Sin 
2004). Finally the positive correlation between sCRP and 
tHCY reported in our study has also been found in other 
chronic diseases (Sattar 2007; Schroecksnadel 2007) and 
this again supports the hypothesis of a possible role for 
homocysteine in cardiac complications in chronic disease 
patients. The cause of this association is not clear. Inter-
ventional studies have so far shown that increased intake 
of folate or B12 while reducing tHCY are not associated 
with however decreased serum inﬂ  ammatory markers or 
cardiac events but raised serum folate may have direct 
effects at multiple sites including atherosclerotic plaques 
and thus other methods of reducing tHCY may yield dif-
ferent results on serum inﬂ  ammatory markers (Durga 2005; 
Bonaa 2006).
In this study of West Indian patients with COPD we 
have found that two markers, tHCY and sCRP, that have 
been associated with cardiovascular risk are also associated 
with COPD and with COPD severity and with each other. 
In general, for a 10% decrease in FEV1, all-cause mortality 
increases by 14%, cardiovascular mortality increases by 
28%, and nonfatal coronary events increase by almost 20% 
(Anthonisen 2002), similarly, studies of sCRP have shown 
that sCRP greater than 3 mg/l is associated with high mortal-
ity rates at 10 years (Dahl 2007). Further studies are required 
to determine the cause of the elevated plasma homocysteine 
GOLD Stages 1 &2, FEV1 >= 50% Predicted
5.00
10.00
15.00
20.00
25.00
30.00
tHCY
(micromol/L)
GOLD Stages 3&4, FEV1 < 50% predicted
Figure 2 The box plot shows the relationship between total plasma homocysteine (tHCY) and COPD severity in 29 COPD patients, p = 0.023. Open circles indicate 
outliers.
Table 4 Backward stepwise multiple regression analysis with 
plasma homocysteine (log) as outcome variable in 54 subjects 
(29 COPD and 25 healthy controls)
Dependent variables  Regression coefﬁ  cient (B)  p
sCRP (log)  0.087  0.024
COPD 0.194  0.031
Male gender  0.345  0.001
Constant 1.848  0.001International Journal of COPD 2007:2(3) 320
Seemungal et al 
levels in COPD patients in this West Indian population and 
whether tHCY is related to mortality in COPD.
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